Deutsches Herzzentrum, Technische Universität, Munich, Germany.
Am J Cardiol. 2010 Nov 1;106(9):1212-7. doi: 10.1016/j.amjcard.2010.06.050. Epub 2010 Sep 9.
Current guidelines recommend troponin T (TnT) as the biomarker of choice in the diagnosis of myocardial infarction. In patients with ST-elevation myocardial infarction (STEMI) however, its role in providing a measurement of infarct size and its association with survival is less well established. We sought to assess the correlation of TnT and creatine kinase-MB (CK-MB) with scintigraphically determined infarct size and to assess the predictive value of all 3 parameters on 12-month mortality. Patients presenting with STEMI managed with primary percutaneous intervention underwent serial TnT and CK-MB measurements at admission and for ≥72 hours after presentation. Before hospital discharge patients underwent assessment of infarct size by technetium-99m sestamibi single-photon emission computed tomographic (SPECT) scan. Clinical follow-up was performed up to 1 year. Data were available for 1,237 patients. Mean age was 62.9 ± 12.9 years. Infarct location was anterior in 509 patients (41%); 75 (6.1%) had cardiogenic shock. Median admission and peak TnT were 0.74 μg/L (0.10 to 2.70) and 3.70 μg/L (1.69 to 6.99), respectively. Corresponding values for CK-MB were 44.1 U/L (21.0 to 108.8) and 160.0 U/L (69.0 to 301.0), respectively. Median infarct size on SPECT scan was 12.0% (3.0 to 25.0) of the left ventricle. Peak TnT and CK-MB demonstrated similar moderate correlation with final infarct size (r = 0.45, p <0.001, and r = 0.41, p <0.001 respectively). This correlation was not affected by Thrombolysis In Myocardial Infarction flow grade after intervention. At 1 year, 47 patients (3.8%) had died. Final infarct size at SPECT scanning better predicted mortality than peak TnT or CK-MB. In conclusion, this study is the largest investigation on the value of cardiac troponin for assessment of infarct size in acute STEMI. Compared to peak CK-MB, peak TnT shows similar correlation with scintigraphic infarct size, although scintigraphic infarct size remains a better correlate of 1-year mortality than either biomarker.
目前的指南建议肌钙蛋白 T(TnT)作为心肌梗死诊断的首选生物标志物。然而,在 ST 段抬高型心肌梗死(STEMI)患者中,其在测量梗死面积方面的作用及其与生存率的关系尚未得到充分证实。我们旨在评估 TnT 和肌酸激酶同工酶-MB(CK-MB)与放射性核素确定的梗死面积的相关性,并评估这 3 个参数在 12 个月死亡率预测方面的价值。
接受经皮冠状动脉介入治疗的 STEMI 患者在入院时和入院后至少 72 小时内连续进行 TnT 和 CK-MB 测量。在出院前,患者接受锝-99m sestamibi 单光子发射计算机断层扫描(SPECT)评估梗死面积。临床随访时间长达 1 年。共获得 1237 例患者的数据。平均年龄为 62.9 ± 12.9 岁。509 例(41%)患者梗死部位在前壁;75 例(6.1%)发生心源性休克。入院时和峰值 TnT 中位数分别为 0.74μg/L(0.102.70)和 3.70μg/L(1.696.99),相应的 CK-MB 值分别为 44.1U/L(21.0108.8)和 160.0U/L(69.0301.0)。SPECT 扫描中位梗死面积为左心室的 12.0%(3.0~25.0)。峰值 TnT 和 CK-MB 与最终梗死面积呈中度相关(r=0.45,p<0.001 和 r=0.41,p<0.001)。这种相关性不受介入后溶栓治疗心肌梗死血流分级的影响。1 年后,47 例(3.8%)患者死亡。SPECT 扫描的最终梗死面积比峰值 TnT 或 CK-MB 更能预测死亡率。
总之,本研究是对急性 STEMI 中心肌肌钙蛋白评估梗死面积价值的最大研究。与峰值 CK-MB 相比,峰值 TnT 与放射性核素梗死面积具有相似的相关性,尽管放射性核素梗死面积与 1 年死亡率的相关性仍优于任何一种生物标志物。